Byredo (Update)
Is Your Restraint a Choice or a Limitation?
Prestige beauty grew 2 percent in H1 2025. Mass grew 4 percent.
In this issue
The Quarter in Brand Authority
The Brand Worth Watching — Byredo (Update)
The Vocabulary Shift
Category Signals
The Blind Spot
The Question
The convergence story visible in Q1 deepened through Q2. Mass fragrance grew 17 percent while prestige fragrance grew 6 percent. The consumer who a year ago bought a $35 body mist at Sephora is now buying a comparable product at Target. Prestige has not lost her. It has lost her attention in the category she used to reserve for prestige.
Prestige skincare declined 1 percent in the first half while mass skincare grew 4 percent. Masstige skincare grew double digits. This is not trading down. It is trading across -- from a prestige product that led with positioning to a masstige product that leads with a specific, named ingredient at a price that feels like value. The consumer has not decided prestige skincare is not worth it. She has decided that some prestige skincare is not worth it, and she is getting better at identifying which.
The brands holding prestige skincare share in H1 2025 have one thing in common: a specific mechanism that justifies the price. Not anti-aging. Not barrier repair. A named, owned, demonstrable thing that cannot be purchased at a lower price point because the underlying science is genuinely proprietary.
Color cosmetics was essentially flat in H1 2025, growing just 1 percent. The structural issue is that the consumer's relationship to makeup has been permanently altered by five years of skincare education. She no longer buys color for color alone. She buys it when it also delivers something functional -- a barrier benefit, a peptide payload, a named active she recognizes from her skincare shelf.
The most significant announcement of the quarter arrived May 28: e.l.f. Beauty purchased Rhode for $1 billion. e.l.f.'s stated purpose is to make the best of prestige accessible to everyone. They just paid $1 billion for a brand whose authority came entirely from being inaccessible. What happens when restraint meets scale is the question the second half of 2025 will begin to answer.
In Q1 2024, Byredo appeared as the first Brand Worth Watching. The diagnosis: Gorham's specific interior life was the product, and that was not transferable to Puig. The copy on the About page -- a living library of collective memories and cultural references -- was cited as evidence that the substitution had already begun.
On June 18, 2025, Ben Gorham officially left the company, completing the handover contracted in the 2022 acquisition agreement.
It is worth returning to the original diagnosis and holding it against what has happened since.
Puig's answer to the diagnostic question, implicit in every communication since the departure, is: a library. The About page copy that appeared to this Brief as a warning sign is now, twelve months later, the only description of the brand Puig has publicly deployed. The specific person whose memories formed the collection has left the building. The library remains.
Puig is expanding the brand's retail footprint aggressively. New flagships in Barcelona and Covent Garden. Growth in the niche category leading Puig's portfolio in H1 2025. The revenue numbers are moving. What the revenue numbers cannot capture is whether the consumer buying Gypsy Water in the new Covent Garden store is paying for a scent or for a story. If she is paying for the scent, Byredo is fine. If she was paying for Gorham's story -- specific and non-replicable -- then the growth numbers will not reflect the erosion until the story has already faded.
What the Brief is watching now is the copy. Specifically: when Byredo launches its next fragrance, what is the brief? Gorham's briefs came from notebooks full of personal memory -- a trip to Mumbai, a street in Stockholm, a conversation with his father. Names like Mojave Ghost, Bal d'Afrique, and Oud Immortel each pointed to a specific, identifiable origin. The names that come next will tell you whether Puig understood what the names were actually doing.
The term entering this quarter: cleanical. The compound word -- clean plus clinical -- is beginning to appear in brand copy and in trade press as a descriptor for a new category of products that combine clean formulation commitments with clinical efficacy claims. Tata Harper is using cleanical positioning explicitly. The term is in its entering stage: it has genuine differentiating potential because it combines two consumer expectations that were previously in tension. A brand that is both certified clean and clinically validated is occupying a more specific position than a brand that is only one of those things.
Exiting: biotech. The term entered in Q1 2025 and is already showing signs of overclaiming. Multiple brands with no proprietary biotechnology are using biotech as primary brand copy. When a term that requires significant scientific investment to earn appears on brands without that investment, the term's authority signal degrades. Biotech is not yet retired, but it is moving from entering to mainstream faster than anticipated, and the window for legitimate differentiation is narrowing.
Skincare, fragrance, color cosmetics, hair, and wellness signals tracked across observation, validation, and forecast.
Skincare — The Prestige-Masstige Convergence
Mass skincare grew 4 percent in H1 2025 while prestige skincare declined 1 percent. The consumer's functional expectations in skincare are now fully portable across price tiers. She evaluates prestige and masstige on the same proof standard and chooses accordingly. Validation: masstige skincare grew double digits through H1 2025. The Ordinary, CeraVe, and La Roche-Posay are growing faster than the prestige brands they sit beneath in positioning maps. Forecast: prestige skincare authority will require differentiation that genuinely cannot be replicated at lower price points. Proprietary mechanisms, brand-specific clinical studies, and credentialed scientists are the only things that hold the prestige price premium.
Fragrance — Identity Fragrance Gaining Share
A specific segment of prestige fragrance is accelerating while the overall category normalizes: niche and luxury brands with a named identity and a specific point of view are growing faster than the category, while mass-facing prestige fragrance is softening. Validation: luxury fragrance brands within prestige grew faster than the overall rate in H1 2025. The consumer who entered fragrance through a $35 body mist three years ago is now seeking something specific and non-replicable. Forecast: the niche and luxury fragrance segment will continue to outperform prestige fragrance broadly through 2026.
Color Cosmetics — Stagnation and Strategic Pressure
Prestige makeup is flat in H1 2025. Mass makeup is declining low single digits. Clinical brands' makeup grew 40 percent in 2024, and Westman Atelier is named again as a top M&A target generating acquisition interest from multiple strategics. Both data points describe the same phenomenon: the consumer trusts brands with documented skin science to make makeup worth buying. Forecast: the color recovery expected in 2026 will lift the brands that built functional premises. The others will require a strategy shift, not a trend to ride.
Hair — Professional Channel as Authority Anchor
The professional channel is reemerging as the primary credentialing mechanism for prestige hair. Olaplex's strategy is explicitly repositioning toward professional authority, reestablishing salon relationships after over-rotation toward specialty retail. Validation: Olaplex's professional channel reversed its decline in Q2 2025. Brands that let professional relationships erode during the DTC-first period of 2020 to 2023 are paying for it now. Forecast: the professional channel will be the most important authority-building mechanism for prestige hair through 2026.
Wellness — Biohacking Goes Mainstream
Biohacking is migrating from a niche self-optimization practice into mainstream wellness vocabulary. Over 40 percent of Gen Z consumers express interest in bio-optimization practices. Search interest in longevity molecules like NMN and NAD+ tripled in 2024 alone. Validation: brands explicitly using biohacking language -- measurable biological outcomes, biomarker tracking, quantified aging interventions -- are generating consumer attention and investor interest simultaneously. Forecast: biohacking will complete its transition to aspirational mainstream within 12 to 18 months. The differentiation advantage belongs to brands that arrive with documented biomarker evidence before the vocabulary becomes ambient.
The category has spent the past 18 months analyzing Drunk Elephant's decline through the lens of a brand that lost its core consumer to a younger one. That is accurate but incomplete.
The Rhode acquisition is generating significant conversation about what e.l.f. paid for: the brand, the founder, the DTC model, the Sephora pipeline. The category is not examining the parallel story unfolding across the acquisition landscape this same quarter. Ben Gorham officially left Byredo at the end of June. Drunk Elephant's founder Tiffany Masterson is increasingly ceremonial inside Shiseido as the brand struggles. The pattern is consistent: brands acquired on the strength of a founder's specific authority are discovering that the corporate owner cannot replicate what made the brand worth acquiring. The category has developed extensive frameworks for valuing founder-led brands at the point of acquisition. It has almost no framework for what happens to brand authority in the two to three years after the founder transitions out. Rhode is about to become the most visible test case for that question. The subscriber who understands the Byredo and Drunk Elephant trajectories is better positioned to read what happens next at Rhode than anyone relying on the acquisition narrative alone.
Rhode just sold for $1 billion on the strength of three years, ten products, and a DTC model with no retail footprint.
The question is not what e.l.f. paid for. The question is: what did Rhode do in those three years that the ten products alone cannot explain?
The answer is that Rhode made restraint feel like authority. The absence of SKUs. The absence of retail. The absence of the category conventions that every other brand was following. The consumer read the restraint as confidence.
What does your brand's restraint signal? And is it restraint by choice or restraint by circumstance?
There is a meaningful difference. Rhode chose not to expand into retail for three years. That choice was visible and intentional. What choices is your brand making -- or not making -- that the consumer can see and interpret?